AIM ImmunoTech CEO and President Thomas K. Equels reports $5,130 common share acquisition
AIM•AIM ImmunoTech CEO, President and director Thomas K. Equels purchased 38,000 common shares at $0.135 each, bringing his direct beneficial ownership to 366,095 shares.




